ANNA KAVANAUGH: Open Payments
NPI 1962827345 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 39 payments from 13 companies in 2025. Trend: 2023 $572 · 2024 $810 · 2025 $1,059
Food & beverage: $970Education: $89
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $257 |
| Galderma Laboratories, L.P. | 4 | $223 |
| GENZYME CORPORATION | 4 | $98 |
| Novartis Pharmaceuticals Corporation | 5 | $97 |
| Amgen Inc. | 4 | $92 |
| GlaxoSmithKline, LLC. | 5 | $86 |
| Genentech USA, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| CSL Behring | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
Products named: DUPIXENT, NEMLUVIO, TEZSPIRE, TRELEGY ELLIPTA, Rhapsido, Xolair, TAKHZYRO, NEFFY.
Industry payments across IN — which companies pay providers there.
